HLB bioStep Statistics
Total Valuation
HLB bioStep has a market cap or net worth of KRW 106.26 billion. The enterprise value is 108.57 billion.
Market Cap | 106.26B |
Enterprise Value | 108.57B |
Important Dates
The last earnings date was Thursday, August 14, 2025.
Earnings Date | Aug 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
HLB bioStep has 84.47 million shares outstanding. The number of shares has increased by 17.05% in one year.
Current Share Class | 84.47M |
Shares Outstanding | 84.47M |
Shares Change (YoY) | +17.05% |
Shares Change (QoQ) | +1.24% |
Owned by Insiders (%) | 4.96% |
Owned by Institutions (%) | 4.61% |
Float | 66.03M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 1.61 |
PB Ratio | 0.96 |
P/TBV Ratio | 1.10 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -11.75 |
EV / Sales | 1.64 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -7.22 |
Financial Position
The company has a current ratio of 2.28, with a Debt / Equity ratio of 0.27.
Current Ratio | 2.28 |
Quick Ratio | 1.79 |
Debt / Equity | 0.27 |
Debt / EBITDA | n/a |
Debt / FCF | -1.99 |
Interest Coverage | -12.32 |
Financial Efficiency
Return on equity (ROE) is -9.31% and return on invested capital (ROIC) is -6.00%.
Return on Equity (ROE) | -9.31% |
Return on Assets (ROA) | -5.40% |
Return on Invested Capital (ROIC) | -6.00% |
Return on Capital Employed (ROCE) | -10.49% |
Revenue Per Employee | 449.17M |
Profits Per Employee | -62.88M |
Employee Count | 147 |
Asset Turnover | 0.40 |
Inventory Turnover | 12.40 |
Taxes
Income Tax | -1.76B |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.07% in the last 52 weeks. The beta is 0.16, so HLB bioStep's price volatility has been lower than the market average.
Beta (5Y) | 0.16 |
52-Week Price Change | -48.07% |
50-Day Moving Average | 1,406.18 |
200-Day Moving Average | 1,832.56 |
Relative Strength Index (RSI) | 33.52 |
Average Volume (20 Days) | 163,892 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HLB bioStep had revenue of KRW 66.03 billion and -9.24 billion in losses. Loss per share was -103.30.
Revenue | 66.03B |
Gross Profit | 47.59B |
Operating Income | -14.19B |
Pretax Income | -12.47B |
Net Income | -9.24B |
EBITDA | -9.30B |
EBIT | -14.19B |
Loss Per Share | -103.30 |
Balance Sheet
The company has 32.03 billion in cash and 29.88 billion in debt, giving a net cash position of 2.15 billion or 25.43 per share.
Cash & Cash Equivalents | 32.03B |
Total Debt | 29.88B |
Net Cash | 2.15B |
Net Cash Per Share | 25.43 |
Equity (Book Value) | 110.86B |
Book Value Per Share | 1,259.68 |
Working Capital | 28.80B |
Cash Flow
In the last 12 months, operating cash flow was -13.98 billion and capital expenditures -1.06 billion, giving a free cash flow of -15.04 billion.
Operating Cash Flow | -13.98B |
Capital Expenditures | -1.06B |
Free Cash Flow | -15.04B |
FCF Per Share | -178.02 |
Margins
Gross margin is 72.07%, with operating and profit margins of -21.49% and -14.00%.
Gross Margin | 72.07% |
Operating Margin | -21.49% |
Pretax Margin | -18.89% |
Profit Margin | -14.00% |
EBITDA Margin | -14.09% |
EBIT Margin | -21.49% |
FCF Margin | n/a |
Dividends & Yields
HLB bioStep does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -17.05% |
Shareholder Yield | n/a |
Earnings Yield | -8.70% |
FCF Yield | -14.15% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on May 31, 2022. It was a forward split with a ratio of 9.
Last Split Date | May 31, 2022 |
Split Type | Forward |
Split Ratio | 9 |
Scores
HLB bioStep has an Altman Z-Score of 2.79 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.79 |
Piotroski F-Score | 3 |